Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis

Figure 1 Flow chart indicating the selection process for this meta analysis.

Figure 2 Mean relative changes from baseline of liver function and model for end-stage liver disease scores during 48 wk follow-up. A: The change-trend of model for end-stage liver disease (MELD) scores, and prothrombin times (PT) and abnormal serum albumin (ALB) levels; B: The change-trend of alanine aminotransferase (ALT) and total bilirubin (TBIL) levels (Data were from Peng et al[19]).

Figure 3 Forest plot of overall model for end-stage liver disease scores during follow up.

Figure 4 Comparison of changes in performance scale and fatigue scale at various times after transfusion of bone marrow-derived mesenchymal stem cells. A: Changes in performance scale; B: Changes in fatigue scale (Data were from Amer et al[18]). BM-MSCs: Bone marrow-derived mesenchymal stem cells.